Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations.

Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, Huang RS, Cox NJ, Dolan ME
Pharmacogenomics J. 2013 13 (1): 35-43

PMID: 21844884 · PMCID: PMC3370147 · DOI:10.1038/tpj.2011.38

Platinating agents are used in the treatment of many cancers, yet they can induce toxicities and resistance that limit their utility. Using previously published and additional world population panels of diverse ancestry totaling 608 lymphoblastoid cell lines (LCLs), we performed meta-analyses of over 3 million single-nucleotide polymorphisms (SNPs) for both carboplatin- and cisplatin-induced cytotoxicity. The most significant SNP in the carboplatin meta-analysis is located in an intron of NBAS (neuroblastoma amplified sequence; P=5.1 × 10(-7)). The most significant SNP in the cisplatin meta-analysis is upstream of KRT16P2 (P=5.8 × 10(-7)). We also show that cisplatin-susceptibility SNPs are enriched for carboplatin-susceptibility SNPs. Most of the variants that associate with platinum-induced cytotoxicity are polymorphic across multiple world populations; therefore, they could be tested in follow-up studies in diverse clinical populations. Seven genes previously implicated in platinating agent response, including BCL2 (B-cell CLL/lymphoma 2), GSTM1 (glutathione S-transferase mu 1), GSTT1, ERCC2 and ERCC6, were also implicated in our meta-analyses.

MeSH Terms (10)

Carboplatin Cell Line Cisplatin Drug Resistance, Neoplasm Follow-Up Studies Genome-Wide Association Study Humans Neoplasm Proteins Organoplatinum Compounds Polymorphism, Single Nucleotide

Connections (2)

This publication is referenced by other Labnodes entities:

Links